Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ANP32B_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ANP32B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ANP32B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ANP32B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ANP32B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ANP32B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ANP32B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ANP32B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ANP32B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ANP32B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190495117 | Prostate | BPH | positive regulation of establishment of protein localization | 101/3107 | 319/18723 | 1.77e-11 | 1.24e-09 | 101 |
GO:005254718 | Prostate | BPH | regulation of peptidase activity | 133/3107 | 461/18723 | 2.08e-11 | 1.43e-09 | 133 |
GO:003315716 | Prostate | BPH | regulation of intracellular protein transport | 76/3107 | 229/18723 | 5.05e-10 | 2.56e-08 | 76 |
GO:004328118 | Prostate | BPH | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 71/3107 | 209/18723 | 5.88e-10 | 2.89e-08 | 71 |
GO:005254818 | Prostate | BPH | regulation of endopeptidase activity | 122/3107 | 432/18723 | 6.10e-10 | 2.91e-08 | 122 |
GO:005122217 | Prostate | BPH | positive regulation of protein transport | 93/3107 | 303/18723 | 6.94e-10 | 3.25e-08 | 93 |
GO:000691315 | Prostate | BPH | nucleocytoplasmic transport | 92/3107 | 301/18723 | 1.09e-09 | 4.84e-08 | 92 |
GO:005116915 | Prostate | BPH | nuclear transport | 92/3107 | 301/18723 | 1.09e-09 | 4.84e-08 | 92 |
GO:200011618 | Prostate | BPH | regulation of cysteine-type endopeptidase activity | 76/3107 | 235/18723 | 1.90e-09 | 7.79e-08 | 76 |
GO:003238816 | Prostate | BPH | positive regulation of intracellular transport | 68/3107 | 202/18723 | 2.08e-09 | 8.35e-08 | 68 |
GO:001095218 | Prostate | BPH | positive regulation of peptidase activity | 66/3107 | 197/18723 | 4.44e-09 | 1.66e-07 | 66 |
GO:00903169 | Prostate | BPH | positive regulation of intracellular protein transport | 55/3107 | 160/18723 | 3.09e-08 | 8.91e-07 | 55 |
GO:004682215 | Prostate | BPH | regulation of nucleocytoplasmic transport | 40/3107 | 106/18723 | 1.35e-07 | 3.20e-06 | 40 |
GO:001095017 | Prostate | BPH | positive regulation of endopeptidase activity | 56/3107 | 179/18723 | 8.24e-07 | 1.54e-05 | 56 |
GO:004682410 | Prostate | BPH | positive regulation of nucleocytoplasmic transport | 26/3107 | 62/18723 | 2.06e-06 | 3.40e-05 | 26 |
GO:004328016 | Prostate | BPH | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 43/3107 | 129/18723 | 2.41e-06 | 3.90e-05 | 43 |
GO:200105616 | Prostate | BPH | positive regulation of cysteine-type endopeptidase activity | 46/3107 | 148/18723 | 9.21e-06 | 1.29e-04 | 46 |
GO:00063259 | Prostate | BPH | chromatin organization | 101/3107 | 409/18723 | 1.52e-05 | 1.94e-04 | 101 |
GO:005116815 | Prostate | BPH | nuclear export | 46/3107 | 154/18723 | 2.86e-05 | 3.32e-04 | 46 |
GO:004682516 | Prostate | BPH | regulation of protein export from nucleus | 13/3107 | 30/18723 | 5.11e-04 | 3.62e-03 | 13 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANP32B | SNV | Missense_Mutation | novel | c.185A>T | p.Lys62Met | p.K62M | Q92688 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANP32B | SNV | Missense_Mutation | novel | c.178N>A | p.Leu60Ile | p.L60I | Q92688 | protein_coding | deleterious(0.03) | possibly_damaging(0.818) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANP32B | SNV | Missense_Mutation | | c.616G>A | p.Asp206Asn | p.D206N | Q92688 | protein_coding | tolerated(0.16) | benign(0.011) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANP32B | SNV | Missense_Mutation | | c.697N>C | p.Glu233Gln | p.E233Q | Q92688 | protein_coding | tolerated(0.1) | benign(0.259) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANP32B | SNV | Missense_Mutation | | c.241G>C | p.Asp81His | p.D81H | Q92688 | protein_coding | deleterious(0.02) | possibly_damaging(0.869) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANP32B | SNV | Missense_Mutation | | c.623N>G | p.Glu208Gly | p.E208G | Q92688 | protein_coding | tolerated(0.17) | probably_damaging(0.932) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ANP32B | SNV | Missense_Mutation | | c.179N>G | p.Leu60Arg | p.L60R | Q92688 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-5403-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ANP32B | SNV | Missense_Mutation | rs761031783 | c.619N>A | p.Asp207Asn | p.D207N | Q92688 | protein_coding | tolerated(0.23) | benign(0.142) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANP32B | SNV | Missense_Mutation | | c.753N>G | p.Asp251Glu | p.D251E | Q92688 | protein_coding | deleterious_low_confidence(0) | benign(0.225) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANP32B | SNV | Missense_Mutation | novel | c.598N>A | p.Val200Ile | p.V200I | Q92688 | protein_coding | tolerated(0.42) | benign(0.001) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |